- Global Pharma News & Resources

Opium (Opioid) Addiction Drug Pipeline Landscape Report 2021 -

DUBLIN--(BUSINESS WIRE)--The "Opium (Opioid) Addiction (Central Nervous System) - Drugs In Development, 2021" report has been added to's offering.

Opium (Opioid) Addiction - Drugs In Development, 2021, provides an overview of the Opium (Opioid) Addiction (Central Nervous System) pipeline landscape.

Opioid Addiction develops after using opioids regularly for a period of time. Prolonged use of opiates can lead to nerve damage within the brain that causes cells to stop producing endogenous opiates (natural painkillers known as endorphins). This can lead to an inability for the body to stop pain because there are no endorphins to mask the pain initially.

The degeneration of the nerve cells that reduce pain can lead to a physical dependence on opiates as an external supply source. Signs and symptoms include increased general anxiety, euphoria, psychosis, depression, high blood pressure, decreased appetite, physical agitation, difficulty sleeping and pain in the bones.

The predisposing factors include age, a personal history of substance abuse, and family history of substance abuse, cigarette dependency and psychologic stress.

Report Highlights

Opium (Opioid) Addiction - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Opium (Opioid) Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Opium (Opioid) Addiction (Central Nervous System) pipeline guide also reviews the key players involved in therapeutic development for Opium (Opioid) Addiction and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 10, 13, 2, 34, 11 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 1 and 6 molecules, respectively. Opium (Opioid) Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction (Central Nervous System).- The pipeline guide reviews pipeline therapeutics for Opium (Opioid) Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.- The pipeline guide reviews key companies involved in Opium (Opioid) Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.- The pipeline guide evaluates Opium (Opioid) Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Opium (Opioid) Addiction (Central Nervous System)

Key Topics Covered:

  1. Introduction
  2. Opium (Opioid) Addiction - Overview
  3. Opium (Opioid) Addiction - Therapeutics Development
  4. Opium (Opioid) Addiction - Therapeutics Assessment
  5. Opium (Opioid) Addiction - Companies Involved in Therapeutics Development
  6. Opium (Opioid) Addiction - Drug Profiles
  7. Opium (Opioid) Addiction - Dormant Projects
  8. Opium (Opioid) Addiction - Discontinued Products
  9. Opium (Opioid) Addiction - Product Development Milestones
  10. Appendix

Companies Mentioned

  • Adial Pharmaceuticals Inc
  • Alar Pharmaceuticals Inc
  • Amygdala Neurosciences Inc
  • Antheia Inc
  • Aoxing Pharmaceutical Company Inc
  • Aphios Corp
  • Aquilus Pharmaceuticals Inc
  • Astellas Pharma Inc
  • Atai Life Sciences BV
  • Benuvia Therapeutics Inc
  • BioCorRx Inc
  • BioXcel Therapeutics Inc
  • Bridge Therapeutics Inc
  • Bright Minds Biosciences Inc
  • Camurus AB
  • Cessation Therapeutics LLC
  • Closed Loop Medicine Ltd
  • Daisy Pharma Inc
  • Delpor Inc
  • DemeRx Inc
  • DMK Pharmaceuticals Inc
  • Elysium Therapeutics Inc
  • Emergent BioSolutions Inc
  • Ensysce Biosciences Inc
  • Eolas Therapeutics Inc
  • Epiodyne Inc
  • Ethismos Research Inc
  • Exxel Pharma Inc
  • Fab'entech SA
  • Fannin Partners LLC
  • Gilgamesh Pharmaceuticals Inc
  • Hunan Saiao Pharmaceutical Co Ltd
  • Indivior Plc
  • Inimmune Corp
  • Jazz Pharmaceuticals Plc
  • Kinoxis Therapeutics Pty Ltd
  • Lyndra Therapeutics Inc.
  • Mayne Pharma Group Ltd
  • Mebias Discovery LLC
  • Mind Medicine MindMed Inc
  • Nirsum Laboratories Inc
  • Omeros Corp
  • Opiant Pharmaceuticals Inc
  • Orexo AB
  • Orphomed Inc
  • Osmotica Pharmaceutical Corp
  • OYE Therapeutics Inc
  • Palisades Therapeutics
  • Pharmazz Inc
  • Phoenix PharmaLabs Inc
  • Plumb Pharmaceuticals LLC
  • Revive Therapeutics Ltd
  • SafeRX Pharmaceuticals Inc
  • Sen-Jam Pharmaceutical LLC
  • Senzer Ltd
  • Serina Therapeutics Inc
  • Syntropharma Ltd
  • Titan Pharmaceuticals Inc
  • VDM Biochemicals Inc
  • Vivreon Biosciences LLC
  • Yichang Humanwell Pharmaceutical Co Ltd
  • Zynerba Pharmaceuticals Inc

For more information about this report visit

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Editor Details

  • Company:
    • Businesswire
Last Updated: 09-Sep-2021